Moreover, altered phospholipid metabolism has been well documented in several neurological and psychiatric diseases [113], including AD, in which PKC signaling is critical for the non-toxic degradation of the amyloid precursor protein (APP) and the inhibition of GSK3β, which controls tau phosphorylation. Here, PRRT2 is linked to Alzheimer disease.